What can St. Jude expect post-Riata?

How concerned is Wall Street about St Jude Medical's ($STJ) heart rhythm devices? Very, especially since physicians might now think twice about using the company's heart devices (bear in mind, there's a $6.5 billion worldwide market for implantable defibrillators at stake). "I stopped using Durata months ago. I stopped using Riata years ago," Reuters quotes one doctor as saying--and those words can't make the company feel much better. "People are wondering, is there more to this story? When you see such a vigorous defense, you wonder what's evoking this? Why are they fighting people who are raising questions? This could leave lasting reputational damage," said Dr. Harlan Krumholz, a cardiologist at the Yale School of Medicine. Analysis

Suggested Articles

The former Fierce 15 winner’s SuperMap program was cleared to guide electrophysiologists in the treatment of stable and transient arrhythmias.

Insulet announced new agreements with Abbott and Dexcom to connect their continuous glucose monitors with its upcoming tubeless, digital insulin pump,

In an SEC filing, Baxter International disclosed that it may have overstated its income over multiple years, inflating it by about $276 million.